Elena Shagisultanova, MD, PhD
Associate Professor, Medicine-Medical Oncology
Medical School:
Department: Medicine-Medical Oncology
- MD, Bashkir State Medical University, Russia (1997)
- PhD, Institute of Biochemistry and Genetics, Russia (2002)
- St Mary's Hospital and Medical Center Program (2010)
- St Mary's Hospital and Medical Center Program, Chief Resident, Internal Medicine (2012)
- Fox Chase Cancer Center Program, Hematology and Oncology (2015)
Department: Medicine-Medical Oncology
Research Interests
My research interests focus on developing new and improved therapies for patients with breast cancer.
Publications
- Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 Jan;21(1):48-57. PubMed PMID: 34728571
- Rasti A, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA mutations drive therapeutic resistance in HER2-positive breast cancer. JCO Precision Oncology (accepted)
- Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. European Journal of Cancer (under revision).
- Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer. 2022 Jun;168:119-127. PubMed PMID: 35525161
- Rasti AR, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Precis Oncol. 2022 Mar;6:e2100370. PubMed PMID: 35357905
- Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 Jan;21(1):48-57. PubMed PMID: 34728571
- E. Shagisultanova, L.S. Crump, M. Borakove, J.K. Hall, A.R. Rasti, B.A. Harrison, P. Kabos, T.R. Lyons and V.F. Borges "Triple targeting of breast tumors driven by hormonal receptors and HER2"
- Kagihara JA, Shagisultanova E, Afghahi A, Diamond JR. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Curr Breast Cancer Rep. 2021 Sep;13(3):216-226. PubMed PMID: 34457184
- Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun;187(3):883-891. PubMed PMID: 33625615
- Richer JN, Spoelstra NS, Winchester A, Wulfkuhle J, Sams SB, Vidal G, Kabos P, Diamond J, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Borges V, Gao D, Petricoin E, Elias AD. Laboratory analyses of metastatic ER+/Her2-breast cancer treated with fulvestrant plus enzalutamide. Cancer Res July 1 2021 (81) (13 Supplement) 2867; DOI: 10.1158/1538-7445.AM2021-2867
- Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Mayordomo J, Diamond JR, Kabos P and Borges VF. Interim safety and efficacy analysis of phase IB / II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer. Cancer Res February 15 2021 (81) (4 Supplement) PS10-03; DOI: 10.1158/1538-7445.SABCS20-PS10-03
- Elias AD, Fournier M, Vidal GM, Sams S, Spoelsta N, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, Wulfkuhle J, Petricoin E, Carter L, Zolman K, Armstead S, Winchester A, McSpadden T, Crawford G, Borges V, Gao D, Richer J. Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC). Cancer Res February 15 2021 (81) (4 Supplement) PS12-06; DOI: 10.1158/1538-7445.SABCS20-PS12-06
- E Shagisultanova, W Gradishar, U Brown-Glaberman, P Chalasani, AJ Brenner, A Stopeck, J Mayordomo, J R. Diamond, P Kabos, VF. Borges. "Interim safety and efficacy analysis of phase IB / II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer". Proceedings of SABCS December 2020.
- West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 Sep;8(12):5609-5618. PubMed PMID: 31407530
- Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast Cancer Res Treat. 2019 Sep;177(2):369-382. PubMed PMID: 31254157
- Shagisultanova E, Mayordomo J, Elias AD. Triple-negative breast cancer in the elderly. Breast J. 2017 Nov;23(6):627-629. PubMed PMID: 29112794
- Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biol Ther. 2017 Sep 2;18(9):694-704. PubMed PMID: 28886275
- Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 2017 Jun 20;8(25):39945-39962. PubMed PMID: 28591715
- Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?. J Natl Compr Canc Netw. 2017 Apr;15(4):494-503. PubMed PMID: 28404760
- Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 Dec 15;30(12). PubMed PMID: 27987198
- Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther. 2016 Oct;15(10):2486-2497. PubMed PMID: 27507850
Practice Locations
UCHealth Diane O'Connor Thompson Breast Center - Anschutz
1635 Aurora Ct
3rd Floor
Aurora, CO 80045
720-848-1030
University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300
UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000
Hospital Affiliation
1635 Aurora Ct
3rd Floor
Aurora, CO 80045
720-848-1030
University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300
UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000
Hospital Affiliation
- University of Colorado Hospital
Specialty Information
Specialties
- Internal Medicine, Board Certification (2012, 2022)
- Hematology and Oncology, Board Certification (2015, 2015)
- Cancers - Breast Cancer
- Cancers
Clinical Interests
Breast cancer
Care Philosophy
Being diagnosed with cancer is a life-changing event, affecting both patients and their families. No one should walk this path alone. It is my honor and privilege to accompany my patients on their cancer journey, and to become a part of their lives in a very special way. In my clinical practice, I focus on the care of patients with breast cancer. I strive to provide expert, prompt, individualized and compassionate care for every patient and family. My philosophy in taking care of patients is, first of all, to listen to them and keep in very close communication throughout the course of treatment. We work together as a team. I help my patient in understanding their diagnosis, and together we design the best plan of action. By working with each patient, their family, and a group of my expert colleagues (surgeons, radiation oncologists, radiologists, pathologists), we can design the most comprehensive treatment plan, that could include both standard treatments and emerging therapies in the form of clinical trials. We live in an exciting time of many outstanding scientific discoveries in cancer diagnostics and therapy. My goal is to bring together all the scientific advances and resources of a cutting-edge cancer center to my patients.
Breast cancer
Care Philosophy
Being diagnosed with cancer is a life-changing event, affecting both patients and their families. No one should walk this path alone. It is my honor and privilege to accompany my patients on their cancer journey, and to become a part of their lives in a very special way. In my clinical practice, I focus on the care of patients with breast cancer. I strive to provide expert, prompt, individualized and compassionate care for every patient and family. My philosophy in taking care of patients is, first of all, to listen to them and keep in very close communication throughout the course of treatment. We work together as a team. I help my patient in understanding their diagnosis, and together we design the best plan of action. By working with each patient, their family, and a group of my expert colleagues (surgeons, radiation oncologists, radiologists, pathologists), we can design the most comprehensive treatment plan, that could include both standard treatments and emerging therapies in the form of clinical trials. We live in an exciting time of many outstanding scientific discoveries in cancer diagnostics and therapy. My goal is to bring together all the scientific advances and resources of a cutting-edge cancer center to my patients.
Personal Interests
In my spare time, I enjoy reading books and being outdoors. I love skiing, hiking, biking and backpacking with my husband and three children.
Public Speaking
Yes
In my spare time, I enjoy reading books and being outdoors. I love skiing, hiking, biking and backpacking with my husband and three children.
Public Speaking
Yes
General Information
Medical Schools:
- MD, Bashkir State Medical University, Russia (1997)
Graduate Schools:
- PhD, Institute of Biochemistry and Genetics, Russia (2002)
Internships:
- St Mary's Hospital and Medical Center Program (2010)
Residency Programs:
- St Mary's Hospital and Medical Center Program, Chief Resident, Internal Medicine (2012)
Fellowships:
- Fox Chase Cancer Center Program, Hematology and Oncology (2015)
Department: Medicine-Medical Oncology